our science 00

VCN Biosciences uses a technological platform based on oncolytic adenoviruses or virotherapy. This novel class of targeted anticancer agents has a unique mechanisms of action compared to other cancer drugs. Oncolytic viruses can detect cancer mutations, replicate or self-amply within cancer cells, lyse them thereby killing them and then propagate the oncolytic effect to neighbouring cancer cells. The therapeutic effect is therefore amplified within tumours reducing the viral dose needed to reach tumours.


Among different viral backbones developed for virotherapy, oncolytic viruses derived from human adenovirus type 5 (Ad5wt) are especially appealing given the limited pathogenicity of this virus and the possibility to control the expression of its genes. 

Currently VCN has four exclusive patent licenses in independent technologies developed internally and in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL) that result in enhanced antitumoral potency of oncolytic adenoviruses. 


Hyaluronidase Albumin Shield Immunoshift T1 Bioselection